David A. Siegel Benitec Biopharma Inc. Transaction History

Two Sigma Advisers, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.13 - $5.95 $3,016 - $138,040	23,200 New	23,200 $3,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $5.81 $46,492 - $68,558	-11,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.59 - $9.26 $141,002 - $504,123	-54,441 Reduced 82.19%	11,800 $61,000
Q4 2020 Feb 16, 2021	BUY	$2.61 - $4.79 $172,889 - $317,294	66,241 New	66,241 $199,000

1.42M

Ticker BNTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,809,500
Market Cap $280M
Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.